Title
London-based biotechnology R and D SME seeking datasets related to gut microbiome through collaborative partnerships
AbstractGlobally, hundreds of millions suffer from gut disorders, with irritable bowel syndrome (IBS) affecting over 10 million people in the UK alone. GutSee Health is revolutionising gut disorder treatment by merging cutting-edge science with advanced AI modelling. Their groundbreaking AI-Discovery platform transforms vast human genetic data into disease signatures and therapy targets. Through their unique and targeted microbiome therapy, they look to restore a healthy gut balance, eliminating symptom
DescriptionGutSee Health is a London-based biotech company revolutionising gut disorder treatments by combining advanced AI modeling with innovative microbiome therapies. As a data-driven company, they are actively seeking IBS and IBD datasets to power their AI discovery platform. They welcome collaborations with academic researchers and enterprises that have datasets on irritable bowel syndrome (IBS) and Inflammatory Bowel Disease (IBD).
Partnership opportunities include patient studies, co-developing R and D projects, joint research publications, academic secondments, and PhD fellowship programs. For example, this could be achieved through applying for research and innovation funding opportunities in collaboration such as Horizon Europe calls or more specific sectorial funding calls.
Advantages and innovation
Technical Specification or Expertise Sought
Access to data, including metagenomic, metabolomic, and patient data related to IBS/IBD or relevant gut disorders.